Resources
About Us
In-Vitro Toxicology/Toxicity Testing Market by Product and Service, Technology (Cell Culture, OMICS), Method (Cell-based Assays, In-Silico), End-point (ADME, Genotoxicity, Organ Toxicity, Dermal Toxicity), End-user, and Geography - Global Forecast to 2025
Report ID: MRHC - 104348 Pages: 189 Nov-2019 Formats*: PDF Category: Healthcare Delivery: 2 to 4 Hours Download Free Sample ReportThe In-Vitro Toxicology Testing Market is expected to grow at a CAGR of 9% from 2019 to reach $14.4 billion by 2025. Factors such as ethical issues and pressure from animal activists’ groups concerning the use of animals for testing, ban on animal testing on cosmetic products, support from regulatory bodies regarding the approval of in-vitro tests, low costs associated with in-vitro toxicology testing, and advancements in in-vitro methodologies are driving the growth of the overall in-vitro toxicology market. Synergetic relationships between various stakeholders of the industry and increasing toxicology databases to facilitate the use of in-vitro test methods are further expected to offer significant growth opportunities for the players operating in this market. Regulatory bodies such as ICCVAM, ECVAM, JaCVAM, and OECD have already approved and validated more than 60 in vitro toxicology tests.
Ban on Animal Testing for Cosmetics Fuels the Growth of the Global In-Vitro Toxicology Testing Market
In 2004, the EU passed a legislation prohibiting the use of finished cosmetic products on animals. In 2009, the testing of cometic ingredients on animals was prohibited within the EU. This was further ammended by forbidding the marketing of cosmetic products tested on animals from March 2013. Complex toxicity end-points such as repeated dose toxicity, reproductive toxicity, and toxicokinetics were exempted from this ban. Other similar initiatives taken by various governments are as below:
In 2013, The Humane Society of the United States (HSUS) and Humane Society International launched a global campaign “Be Cruelty-Free” in agreement with the EU ban on selling animal tested cosmetics. The HSUS and Humane Society Legislative Fund are partnering with scientists, government officials, and industry leaders to make the U.S. the next biggest cruelty-free nation. Such initiatives by various governments to ban the use of animals for cosmetics testing are contributing to the increasing adoption of in vitro toxicology tests.
Click here to: Get Free Sample Pages of this Report
Need to Develop Early Toxicology Testing Methods Supports the Market Growth
Drug development is always associated with the highest risk of failure in the later stages where the capital at stake is high. Toxicity testing accounts for ~30% of expensive, late-stage failures in drug development and market withdrawal, which may result in high attrition rate in the late-stages of the pharmaceutical drug discovery process. According to NCBI, for every 10,000 compounds synthesized in the discovery phase, only 250 reach the preclinical phase, ultimately resulting in one approved drug by the FDA. Therefore, to lower the risk of the same, it is very important to identify and prioritize efforts to bring the attrition of failing molecules at an early stage in drug development. According to the CMR International, 22% of the drug candidates that entered clinical development from 2006 to 2012 failed due to non-clinical toxicology or clinical safety issues. In preclinical development, toxicity and safety issues accounted for 54% of failures (18% of all preclinical candidates). These expensive late-stage failures account for a large proportion of the pharmaceutical R&D cost, and is estimated to be USD 1.8 billion per marketed drug.
The industry is seeking additional efficiencies in preclinical R&D by identifying solutions in the discovery phase to better qualify new molecular entities prior to animal and human testing. The goal of the new R&D model is to increase the chances of a phase I candidate to reach approval by increasing the rigor of qualifying compounds in the preclinical stages. In order to facilitate this, research is increasing in early stages, which is in turn driving the growth of in-vitro toxicology testing market. As the evolving technologies of in-vitro screening and modeling, various in-vitro assays are emerging as a rapid, high-efficient and cost-effective choice of estimating drug safety risks recommended by most regulatory authorities. In May 2019, Scientists in the Department of Biosystems Science and Engineering at ETH Zurich in Basel have now developed a test that allows them to examine a drug's embryotoxicity in cell cultures instead of animals. This new procedure is simple, fast, and inexpensive, enabling researchers to use it to test a large number of drug candidates at an early drug development stage.
Low Cost Associated with In-Vitro Methodologies is Catching the Attention
Animal tests are very expensive and time consuming. It can take anything from a few months to 4-5 years to conduct in-vivo toxicology, and can cost hundreds of thousands—and sometimes millions—of dollars per substance examined. In spite of such huge expenditure, many drugs fail at later stages of drug discovery phases. The inefficiency and exorbitant costs associated with animal testing makes it impossible for regulators to adequately evaluate the potential effects of more than 100 thousand chemicals. In contrast, in vitro methods are amenable to high throughput automation using robotics at a much lower cost than animal tests.
Key Findings in the Global In-Vitro Toxicology Testing Market Study:
OMICS Technologies to Post the Fastest Growth
OMICS technologies aim to understand and predict toxicity by using omics data in order to study systems-level responses. Recent years have witnessed a rapid increase in publicly available omics data, particularly gene expression data, and a corresponding development of methods for toxicological analysis. The application of omics-based technologies in toxicological research has the potential to provide tools to tackle uncertainties from in-vivo toxicological evaluations. As gene expression rapidly changes in response to toxic exposure, it can be used as a sensitive endpoint.
Cell-based Assays Dominates the Global In-Vitro Toxicology Testing Market
The cell-based assays segment is estimated to account for the largest share of the overall in-vitro toxicology testing market in 2019. Cell-based assays help detect and measure cell viability, functionality, and growth. This method of toxicity detection is faster, more effective, and less expensive as compared to biochemical and ex vivo methods. These assays allow integration of targets and pathways in a more physiological setting as compared to biochemical assays. Advancements in cell-based technologies such as high-content screening and label-free detection are expected to further drive the market growth for cell-based assays.
Cosmetics Industry to Witness the Fastest Growth through 2025
The increasing use of cosmetics owing to the rising disposable incomes and their easy availability to the public has driven the industry to invest in the research of breakthrough products and develop human safe products. The subsequent rise in the animal testing of cosmetics and household products during the 1980s and 1990s, especially in the EU, has stimulated the regulatory authorities to enforce strict laws that ban animal testing of these products. Additionally, the demand for cruelty-free cosmetics and personal care products has skyrocketed.
Asia Pacific: The Fastest Growing Regional Market
Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period of 2019 to 2025, owing to increasing biotech investments in this region and increasing collaborations between local and foreign companies. Countries like China, India, South Korea etc. are a hub for biotechnology R&D investments in this region. Many countries in this region have already banned the use of animals for toxicity testing in cosmetics, while many are considering a ban. Thus, factors such as huge R&D investments and initiatives to develop in-vitro methods are expected to boost the in-vitro toxicology testing market in this region.
Key Players
The report includes competitive landscape based on extensive assessment of the key strategic developments adopted by the leading market participants in the industry over the past 5 years. The key players profiled in the global in-vitro toxicology testing market research report are SGS S.A., Covance, Inc. (A Part of Laboratory Corporation of America Holding), Bio-Rad Laboratories, Inc., Qiagen N.V., GE Healthcare, Eurofins Scientific SE, Merck KGAA, Thermo Fisher Scientific, Inc., Charles River Laboratories International, Inc., and Catalent, Inc. among others.
Scope of the Report:
Market by Product & Service
Market by Technology
Market by Method
Market by End-point
Market by End-user
Market by Geography
Key questions answered in the report
Ban on animal testing for cosmetics and need to develop early toxicology testing methods will propel the in-vitro toxicology/toxicity testing Market
Consumables segment accounted for the largest share of the in-vitro toxicology/toxicity testing market
The Europe in-vitro toxicology/toxicity testing market favors both larger and local manufacturers that compete in multiple segments
Published Date: Sep-2024
Published Date: Jun-2024
Published Date: Jun-2024
Published Date: Apr-2023
Please enter your corporate email id here to view sample report.
Subscribe to get the latest industry updates